Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
MWN-AI** Summary
Nona Biosciences has announced a research collaboration with Atossa Therapeutics Inc. aimed at discovering innovative next-generation antibody therapies for breast cancer. This partnership leverages Nona's proprietary H2L2 Harbour Mice® platform, which utilizes transgenic mice to produce fully human monoclonal antibodies. This advanced platform can generate antibodies in both conventional two heavy and two light chain (H2L2) formats and a heavy chain-only (HCAb) format, enhancing the efficiency of therapeutic development without the need for additional humanization processes.
Nona's Harbour Mice® platform has been successfully applied in over 250 drug discovery programs across various therapeutic areas, establishing a strong track record among its global partners. According to Dr. Jingsong Wang, Chairman of Nona Biosciences, this collaboration emphasizes the significance of their proprietary technology in addressing the industry’s increasing demand for innovative antibody discovery solutions. Nona aims to support Atossa’s exploration of antibody-based approaches to enhance its oncology pipeline.
Nona Biosciences is committed to advancing biotechnology through comprehensive services that extend from initial idea validation to investigational new drug (IND) applications. Their integrated solutions encompass the entire spectrum of antibody discovery, including antigen preparation, animal immunization, single B cell screening, lead generation, and pharmacological evaluation. By combining its Harbour Mice® platform with a robust therapeutic antibody discovery team, Nona Biosciences is focused on paving the way for transformative next-generation drugs.
This partnership between Nona Biosciences and Atossa Therapeutics underscores a significant effort in the quest for effective breast cancer therapies, promising to make strides in the understanding and treatment of this prevalent disease. For more details, visit Nona Biosciences' website.
MWN-AI** Analysis
The recent partnership between Nona Biosciences and Atossa Therapeutics presents a compelling case for investors interested in the biotechnology sector, particularly in innovative cancer therapies. This collaboration aims to leverage Nona’s proprietary Harbour Mice® platform—an advanced technology for generating fully human monoclonal antibodies—to discover next-generation therapeutics for breast cancer, a significant area of unmet medical need.
Atossa Therapeutics, known for its focus on breast cancer, stands to benefit significantly from this partnership as it incorporates advanced antibody discovery solutions into its oncology pipeline. The increasing prevalence of breast cancer combined with the emergent demands for innovative treatments provides a fertile ground for development. Given the proprietary nature and proven track record of Nona's platform—employed in over 250 drug discovery programs—this collaboration may accelerate time-to-market for new therapies, potentially offering a competitive edge.
For investors, several factors should be considered. The biotech space can be volatile, with stock prices heavily influenced by clinical trial results and regulatory approvals. However, the collaboration highlights an alignment of expertise and resources between the two companies, which may bolster their chances of successful outcomes.
Moreover, as healthcare continues to move towards personalized medicine, the ability to swiftly develop novel therapeutic candidates aligns well with market trends focusing on targeted therapeutics. Analysts may view this partnership positively, forecasting potential upward momentum in both companies' stock valuations if successful preclinical results are achieved.
In conclusion, investors may consider Nona Biosciences and Atossa Therapeutics as promising options in the biotech space, particularly in light of their innovative approaches to breast cancer treatment amid growing market demand for effective therapies. Careful monitoring of their progress will be essential for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
CAMBRIDGE, Mass. , April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM ), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona's proprietary H2L2 Harbour Mice ® platform to identify next-generation therapeutic candidates for breast cancer.
Nona Biosciences' proprietary Harbour Mice ® platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing therapeutic antibodies and accelerating drug discovery and development. To date, Harbour Mice ® platform has been applied in more than 250 drug discovery programs across multiple therapeutic areas and has been widely recognized by global partners.
"We are pleased to collaborate with Atossa Therapeutics to discover next-generation antibody therapies for breast cancer," said Jingsong Wang , M.D., Ph.D., Chairman of Nona Biosciences. "This partnership highlights the value of our proprietary Harbour Mice ® platform and reflects the industry's growing demand for innovative antibody discovery solutions. With Nona's industry-leading technology and expertise, we look forward to supporting Atossa's exploration of antibody-based approaches within their oncology pipeline."
About Nona Biosciences
Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing a total solution from "Idea to IND" ("I to I TM "), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice ® platforms and the experienced therapeutic antibody discovery team.
Harbour Mice ® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. Integrating Harbour Mice ® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: www.nonabio.com .
SOURCE Nona Biosciences
FAQ**
How will the partnership between Nona Biosciences and Atossa Therapeutics Inc. (ATOS) leverage the Harbour Mice® platform to address the current challenges in developing antibody therapies for breast cancer?
What specific types of next-generation therapeutic candidates for breast cancer are Nona Biosciences and Atossa Therapeutics Inc. (ATOS) aiming to discover through their collaboration?
Can you elaborate on how the single B cell cloning technology will enhance the development of therapeutic antibodies within the partnership between Nona Biosciences and Atossa Therapeutics Inc. (ATOS)?
What metrics or milestones will Nona Biosciences and Atossa Therapeutics Inc. (ATOS) use to measure the success of their research collaboration in discovering innovative antibody therapies?
**MWN-AI FAQ is based on asking OpenAI questions about Atossa Therapeutics Inc. (NASDAQ: ATOS).
NASDAQ: ATOS
ATOS Trading
-2.35% G/L:
$4.98 Last:
5,103 Volume:
$5.11 Open:
